Sabitlenmiş Tweet
We're hiring post-docs and research technicians! Contact me if you're interested in joining our team.
English
Riz Haq MD PhD
97 posts
Riz Haq MD PhD
@rhaq1
Melanoma physician-scientist @DanaFarber Asst Prof @harvardmed. Graduate @OslerResidency @UofTMDprogram. views are my own.
Boston, MA Katılım Ocak 2012
347 Takip Edilen379 Takipçiler
Thank you to the Isaacson's for the generous support of this ocular melanoma fellowship! danafarberimpact.org/2025/06/rare-e…
English
We’re hiring post-docs! Join our lab on projects involving immunotherapy and therapy resistance and metastasis in cutaneous and uveal melanoma. Please DM if interested!
English
5/The project was only possible because of collaboration with the Van Allen lab, talented co-first authors Julia Schiantarelli, Mouadh Benamar, Jihye Park. I am also grateful to patients who donated biopsy material and funding sources, including @MelanomaReAlli @DanaFarberNews
English
3/Strikingly, we found resistance-associated mutations in SEC24C and SEC24D in 3 patients. Melanoma cells engineered to express the SEC24C mutations observed in patients exhibit diminished STING signaling, including decreased Type I interferon production, antigen presentation
English
2/Over several years, we collected matched pre-treatment and post-resistance tumor biopsies in patients with metastatic melanoma who exhibited heterogeneous ICI responses to nominate additional mediators of acquired resistance.
English
1/Although some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors, most exhibit intrinsic or acquired resistance to these therapies.
English
Our paper on a new mechanism of resistance to immunotherapy in melanoma is now in print @Cancer_Cell with the Van Allen lab @VanAllenLab
cell.com/cancer-cell/fu…
Details of the paper below
English
Riz Haq MD PhD retweetledi
Now online in @CD_AACR: A Next-Gen #BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients w/BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation - by @RonaYaeger, S. Michael Rothenberg, et al. doi.org/10.1158/2159-8… @MSKCancerCenter @PfizerOncMed
English
@MRFCureOM @DanaFarber Thank you to the MRF and CURE OM in organizing an amazing event that catalyzes the fight against this disease. We are grateful for your support!
English
Riz Haq MD PhD retweetledi
For #ScienceSunday, Dr. Haq from @DanaFarber & one of the recipients of our inaugural Options Bring Hope Team award, speaks with our attendees about his award winning research titled “Identification of Molecular pathways that drive uveal melanoma Metastasis.” #EyeGetDilated #OM
English
Hope you can join us. Should be a great event for uveal melanoma patients and their families/caregivers. x.com/MRFCureOM/stat…
CURE Ocular Melanoma@MRFCureOM
A special thank you to our partners,@DanaFarber, @MassEyeAndEar, @MassGeneralNews & @TuftsMedicalCtr for collaborating w/ us for this year’s event. Register today so that you can join us for informative sessions around #OM treatment, diagnosis & more -buff.ly/42Zb063
English
@CureMelanoma @DanaFarber @MassEyeAndEar Thank you to CURE OM and the Zubeck and Miller families for supporting this work! We hope that this work will make a difference in our efforts to treat this disease more effectively!
@DanaFarberNews
English
We are excited to announce & congratulate the winners of the inaugural CURE OM Options Bring Hope Team Award: Bruce Ksander, PhD from The Schepens Eye Research Institute , Rizwan Haq MD, PhD from @DanaFarber and Margarete Karg, PhD from @MassEyeAndEar for their research project titled, “Identification of molecular pathways that drive uveal melanoma metastasis.”
The goal of their work is to figure out the main factors that drive uveal melanoma (UM) to spread and specifically target the liver, with the hopes that this research could potentially guide the development of effective therapeutic interventions.
This research award is made in honor of OM patient and advocate, Lindsay Zubeck, and is generously funded by the Family and Friends of the Zubeck and Miller families along with the fantastic OM community.
The CURE OM Options Bring Hope Team Award is intended to advance treatment for all patients with metastatic uveal melanoma, not limited by HLA type. Learn more about their research: buff.ly/49fBOAU
English
@MRFCureOM Thank you to CURE OM and the Zubeck and Miller families for supporting this work! We hope that this work will make a difference in our efforts to treat this disease more effectively! @DanaFarberNews
English
Learn more about this amazing team of researchers and how their research impacts the #OM community during our upcoming Eyes on a Cure: Patient and Caregiver Symposium. Details coming soon!
Melanoma Research Foundation@CureMelanoma
We are excited to announce & congratulate the winners of the inaugural CURE OM Options Bring Hope Team Award: Bruce Ksander, PhD from The Schepens Eye Research Institute , Rizwan Haq MD, PhD from @DanaFarber and Margarete Karg, PhD from @MassEyeAndEar for their research project titled, “Identification of molecular pathways that drive uveal melanoma metastasis.” The goal of their work is to figure out the main factors that drive uveal melanoma (UM) to spread and specifically target the liver, with the hopes that this research could potentially guide the development of effective therapeutic interventions. This research award is made in honor of OM patient and advocate, Lindsay Zubeck, and is generously funded by the Family and Friends of the Zubeck and Miller families along with the fantastic OM community. The CURE OM Options Bring Hope Team Award is intended to advance treatment for all patients with metastatic uveal melanoma, not limited by HLA type. Learn more about their research: buff.ly/49fBOAU
English
Dr. Jedd Wolchok, an esteemed physician-scientist who pioneered immunotherapy for the treatment of melanoma, is the new director of the @WCM_MeyerCancer. Join us in welcoming him to this leadership role that unites cancer research across the institution. bit.ly/3Biviv9
English
English
D-2 ⚠️Researchers in Barcelona interested in cancer biology, do not miss the opportunity to listen to Dr. Haq latest findings! See you there @CampusClinicUB
Caroline Mauvezin@CarolineMvz
📣#seminaralert! We have the immense pleasure to host Dr Haq @rizwanhaq from Dana Farber Cancer Institute to talk about strategies to overcome drug resistance in melanoma! Mark your 🗓️ @hospitalclinic @CellComBcn @ICO_oncologia @idibaps @idibell_cat @IRBBarcelona @CRGenomica
English
@CampusClinicUB @JoanMonte @UBneuroscience @idibaps @hospitalclinic @Creatio_UB Had such a great time talking science at visit @CampusClinicUB. Thank you @JoanMonte for hosting!
English
#SeminarisFMiCS| Recordeu que avui a les 12h l'Aula Magna del @CampusClinicUB acollirà el segon seminari del Cicle Continuat de Conferències de la #FMiCS.
🗣️Identifying and overcoming resistance to melanoma therapies, de la mà del Dr. Rizwan Haq del Dana-Farber Cancer Institute.
Català
Riz Haq MD PhD retweetledi
In the May issue of Cancer Discovery, Adapted to survive: targeting cancer cells with BH3 mimetics by @JoanMonte and @rhaq1.
bit.ly/3N6GYUw
@DanaFarber @harvardmed @IBECBarcelona
English
@DrTonyLetai Thanks Tony for your comments throughout preparation of this manuscript!
English
Nice job, guys!!!
Joan Montero@JoanMonte
Following yesterday's succesfull @TheSFPM meeting, I am pleased to say our review on BH3 mimetics with @rhaq1 is out on @CD_AACR. Looking beyond actual precision medicine for new therapeutic strategies for cancer patients aacrjournals.org/cancerdiscover…
English